Early Experience with a Novel Treatment for Menière’s Disease: A Long Acting Dexamethasone Formulation for Precise Delivery to the Round Window Membrane

∗Division of Surgery, Medical School, University of Western Australia, Perth, Australia

†Department of Otolaryngology–Head and Neck Surgery, University of California

‡Spiral Therapeutics Inc., South San Franciso, California

§Department of Otorhinolaryngology–Head & Neck Surgery, Singapore General Hospital, Singapore

∥Myra Vision, Campbell, California

Address correspondence and reprint requests to Jafri Kuthubutheen, MBBS(Hons), PhD, FRACS, Level 1, 76 South Terrace, South Perth, Western Australia 6151; E-mail: [email protected]

Sources of funding support: Spiral Therapeutics Inc.

Disclosures: C.J.L. is a Chief Medical Officer at Spiral Therapeutics, Inc. J.D.S. is the Senior Vice President of Clinical Science, Spiral Therapeutics, Inc. Medical Advisory Board, Otolith Labs, Inc. Research support from Advanced Bionics, LLC. and Eli Lilly, Inc.

留言 (0)

沒有登入
gif